Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus
Phase 1
Terminated
- Conditions
- Cutaneous LupusDiscoid LupusLupusSystemic Lupus Erythematosus
- Interventions
- Drug: AMG811 Placebo
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2014-09-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 16
- Registration Number
- NCT01164917
- Locations
- 🇺🇸
Research Site, Salt Lake City, Utah, United States
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 72
- Registration Number
- NCT01164904
- Locations
- 🇳🇿
Research Site, Christchurch, New Zealand
Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
Phase 2
Terminated
- Conditions
- Crohn's Disease
- Interventions
- Biological: BrodalumabDrug: Placebo
- First Posted Date
- 2010-06-25
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 130
- Registration Number
- NCT01150890
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
Phase 2
Completed
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- Biological: Romiplostim
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 75
- Registration Number
- NCT01143038
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 23
- Registration Number
- NCT01137565
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 44
- Registration Number
- NCT01137552
- Locations
- 🇺🇸
Research Site, Cleveland, Ohio, United States
Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100
Phase 1
Completed
- Conditions
- Drug Toxicity
- Interventions
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 98
- Registration Number
- NCT01135680
- Locations
- 🇺🇸
Covance Clinical Pharmacology, Inc., Madison, Wisconsin, United States
Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin
Phase 1
Completed
- Conditions
- Hyperlipidemia
- Interventions
- Biological: PlaceboBiological: Evolocumab
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 60
- Registration Number
- NCT01133522
Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 44
- Registration Number
- NCT01129349
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸Oncology Research Associates, Scottsdale, Arizona, United States
Single-dose, Pharmacokinetics of AMG 853 in Healthy Adult Subjects
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 43
- Registration Number
- NCT01124279
© Copyright 2025. All Rights Reserved by MedPath